Frazier Management Lowers stake in Amicus Therapeutics (FOLD)

Amicus Therapeutics (FOLD) : Frazier Management reduced its stake in Amicus Therapeutics by 6.6% during the most recent quarter end. The investment management company now holds a total of 2,725,591 shares of Amicus Therapeutics which is valued at $18,915,602 after selling 192,700 shares in Amicus Therapeutics , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Amicus Therapeutics makes up approximately 16.63% of Frazier Management’s portfolio.

Other Hedge Funds, Including , Secor Capital Advisors Lp added FOLD to its portfolio by purchasing 75,692 company shares during the most recent quarter which is valued at $507,893. Amicus Therapeutics makes up approx 0.07% of Secor Capital Advisors Lp’s portfolio.Asymmetry Capital Management reduced its stake in FOLD by selling 103,887 shares or 31.15% in the most recent quarter. The Hedge Fund company now holds 229,626 shares of FOLD which is valued at $1,607,382. Amicus Therapeutics makes up approx 2.75% of Asymmetry Capital Management’s portfolio.State Board Of Administration Of Florida Retirement System boosted its stake in FOLD in the latest quarter, The investment management firm added 14,810 additional shares and now holds a total of 55,248 shares of Amicus Therapeutics which is valued at $386,736.Columbus Circle Investors boosted its stake in FOLD in the latest quarter, The investment management firm added 56,653 additional shares and now holds a total of 219,986 shares of Amicus Therapeutics which is valued at $1,493,705. Amicus Therapeutics makes up approx 0.01% of Columbus Circle Investors’s portfolio.

Amicus Therapeutics closed down -0.13 points or -1.86% at $6.87 with 12,26,950 shares getting traded on Wednesday. Post opening the session at $6.99, the shares hit an intraday low of $6.79 and an intraday high of $7.13 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Amicus Therapeutics reported $-0.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.04 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.36.Analysts expectations of $ .17.

Many Wall Street Analysts have commented on Amicus Therapeutics. BofA/Merrill Initiated Amicus Therapeutics on May 18, 2016 to “Buy”, Price Target of the shares are set at $10.

Amicus Therapeutics Inc. is a biopharmaceutical company. The Company focuses on the discovery development and commercialization of medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders (SDs). The Company’s lead product candidate is the pharmacological chaperone migalastat HCl (Galafold) a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company’s development programs also include ERTs for LSDs including Fabry disease Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company’s programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease SD-101 for Epidermolysis Bullosa (EB) as well as ERT products for Fabry disease Pompe disease and MPS I.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *